Ensign Peak Advisors Inc Trims Stake in Zoetis Inc. (NYSE:ZTS)

Ensign Peak Advisors Inc decreased its holdings in Zoetis Inc. (NYSE:ZTS) by 8.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 397,164 shares of the company’s stock after selling 35,188 shares during the period. Ensign Peak Advisors Inc owned about 0.09% of Zoetis worth $68,852,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Webster Bank N. A. boosted its holdings in shares of Zoetis by 89.1% in the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after purchasing an additional 82 shares during the period. Neo Ivy Capital Management purchased a new stake in shares of Zoetis in the 4th quarter worth $40,000. LRI Investments LLC bought a new position in shares of Zoetis during the 1st quarter worth $43,000. Ables Iannone Moore & Associates Inc. purchased a new position in shares of Zoetis during the fourth quarter valued at $51,000. Finally, Hazlett Burt & Watson Inc. increased its stake in shares of Zoetis by 60.7% during the first quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock valued at $46,000 after buying an additional 102 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Down 0.3 %

NYSE:ZTS opened at $192.64 on Friday. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The company has a market cap of $87.90 billion, a PE ratio of 37.12, a P/E/G ratio of 2.98 and a beta of 0.88. The company’s 50 day moving average is $184.70 and its two-hundred day moving average is $174.40.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. During the same period in the previous year, the company earned $1.41 earnings per share. The business’s quarterly revenue was up 8.3% compared to the same quarter last year. Analysts anticipate that Zoetis Inc. will post 5.84 EPS for the current year.

Analyst Ratings Changes

Several brokerages have issued reports on ZTS. Stifel Nicolaus increased their target price on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday. Argus raised shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Piper Sandler upped their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Finally, BTIG Research lifted their price target on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Zoetis has a consensus rating of “Buy” and a consensus target price of $220.38.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.